Breast Cancer
Conditions
Brief summary
The purpose of this study is to collect clinical data, blood samples, and self reported symptoms of peripheral neuropathy from Chinese patients with breast cancer after treatment with taxanes. This data will be used to develop predictive markers for neuropathy.
Interventions
FACT-Ntx, EORTC-CIPN20
OTHERBlood Collection
biomarker analysis
Sponsors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
16 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Diagnosis of breast cancer * Females aged 16 and older * Planning to receive or previous treated with taxanes
Exclusion criteria
* Poorly controlled or insulin-dependent diabetes or other condition likely to predispose to neurotoxicity
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total score from the FACT-GOG-Ntx questionnaire | Up to 2 years | Total score from the FACT-GOG-Ntx questionnaire for peripheral neuropathy, ranging from 0-44,higher value represents a worse outcome |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Predictive value of genetic variants for the development of neuropathy | In the two weeks before start treatment | SNPs related to peripheral neuropathy |
| Total score from the EORTC QLQ - CIPN20 questionnaire | Up to 2 years | Total score from the EORTC QLQ - CIPN20 questionnaire for peripheral neuropathy, ranging from 20-80,higher value represents a worse outcome |
Countries
China
Contacts
Primary ContactHongnan Mo, MD
Outcome results
None listed